Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On January 20, 2026, Interpace Biosciences, Inc. (the “Company”) issued a press release (the “Press Release”) ann
Regulation FD Disclosure. In the Press Release, the Company also announced that all of the outstanding shares of its Series C Preferred Stock were converted int
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated January 20, 2026. 104 Cover Page Interactive Data File (embe